Journal List > Cancer Res Treat > v.50(2) > 1153665

TOOLS
Jung, Won, Kong, Lee, and The Community of Population-Based Regional Cancer Registries: Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015
Special Article

Cancer Res Treat 2018;50(2):303-316.

Published online: 21 March 2018

DOI: https://doi.org/10.4143/crt.2018.143

Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015

Kyu-Won Jung, MS1, 2, Young-Joo Won, PhD1, 2, 3, Hyun-Joo Kong, MS1, 2, Eun Sook Lee, MD, PhD1, 4; The Community of Population-Based Regional Cancer Registries*

1The Korea Central Cancer Registry, National Cancer Center, Goyang, Korea

2National Cancer Control Institute, National Cancer Center, Goyang, Korea

3Department of Cancer Control and Population Health, National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

4National Cancer Center Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Korea

Correspondence: Young-Joo Won, PhD The Korea Central Cancer Registry, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea Tel: 82-31-920-2015 Fax: 82-31-920-2179 E-mail: astra67@ncc.re.kr

* The members of the group are listed at the end of this article.

Received 6 March 2018       Accepted 21 March 2018

Copyright © 2018 by the Korean Cancer Association

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

This study presents the 2015 nationwide cancer statistics in Korea, including the incidence, survival, prevalence, and mortality.

Materials and Methods

Cancer incidence data from 1999 to 2015 was obtained from the Korea National Cancer Incidence Database and followed until December 31, 2016. Mortality data from 1983 to 2015 were obtained from Statistics Korea. The prevalence was defined as the number of cancer patients alive on January 1, 2016, among all cancer patients diagnosed since 1999. Crude and age-standardized rates (ASRs) for incidence, mortality and prevalence and 5-year relative survivals were also calculated.

Results

Herein, 214,701 and 76,855 Koreans were newly diagnosed and died from cancer in 2015, respectively. The ASRs for cancer incidence and mortality in 2015 were 258.9 and 82.0 per 100,000, respectively. The overall cancer incidence rate has increased significantly by 3.4% annually from 1999 to 2012, and started to decrease after 2012 (2012-2015, annual percent change, –6.1%). However, the overall cancer mortality has decreased 2.7% annually since 2002. The 5-year relative survival rate for patients diagnosed with cancer between 2011 and 2015 was 70.7%, an improvement from the 41.2% for patients diagnosed between 1993 and 1995.

Conclusion

Age-standardized cancer incidence rates have decreased since 2012 and mortality rates have declined since 2002; however, the 5-year survival rates have improved remarkably from 1993-1995 to 2011-2015 in Korea.

Keywords: Incidence, Survival, Prevalence, Mortality, Neoplasms, Korea

Introduction

Cancer is a major life-threatening disease worldwide. Approximately 14.1 million patients were newly diagnosed with cancer and 8.2 million people died from cancer in 2012 worldwide [1]. The global burden of cancer is expected to grow rapidly due to aging population [2].
In Korea, cancer accounts for one in four deaths and more than 200,000 new cancer cases were diagnosed in 2014 [3]. The number of cancer incidences and deaths are expected to increase with the aging population and westernized lifestyles [4]. Additionally, the economic burden of cancer in Korea increased approximately 1.8-fold, from $11,424 to $20,858 million, between 2000 and 2010 [5].
In this context, cancer statistics are the most important indicator of the national cancer burden and can be used to form cancer prevention and control strategies. This study aims to provide nationwide cancer statistics including the incidence, survival, prevalence, and mortality in 2015.

Materials and Methods

1. Data sources

The Korea Central Cancer Registry (KCCR) was established by the Ministry of Health and Welfare in 1980 as a nationwide hospital-based cancer registry. Since 1999, the KCCR has collected cancer incidence data for the entire nation by compiling a nationwide hospital-based KCCR database that contains data from regional cancer registry programs. The KCCR currently provides the nationwide cancer incidence, survival, and prevalence statistics annually [6].
The KCCR constructed the Korea National Cancer Incidence Database (KNCI DB) using hospitals data, 11 population-based registries, and additional medical chart reviews. The KNCI DB contains information regarding the age, sex, address, date of diagnosis, primary cancer site, histological type, most valid diagnostic method, and Surveillance, Epidemiology, and End Results (SEER) stage. The completeness of cancer incidence data for 2015 was estimated to be 98.2% based on the method proposed by Ajiki et al. [7]. The mid-year population and cancer mortality data from 1983 to 2015 were obtained from Statistics Korea [8]. To ascertain vital status and to calculate survival and prevalence, the KNCI DB was linked to the mortality data and population registration data established by the Ministry of the Interior and Safety.

2. Classification

All incident cases were registered according to the International Classification of Diseases for Oncology, third edition [9], and converted to the International Classification of Diseases, 10th edition (ICD-10) codes [10]. The mortality cases were registered according to ICD-10 codes. All cancer cases were reported based on the 24 cancer types.

3. Statistical analyses

Rates were expressed as crude and age-standardized rates (CR and ASR, respectively) per 100,000 individuals. The CR was calculated as the total number of incidence/mortality cases divided by the mid-year population for the specified years. The ASR is a weighted average of the age-specific rates, where the weights are the proportions of persons in the corresponding age groups of a standard population [11]. In this report, ASRs were calculated using Segi’s world standard population [12]. The cumulative risk of developing cancer from birth to life expectancy was calculated using cumulative rates; that is, the sum of the age-specific rates from birth to life expectancy, as follows [13]:
Cumulative risk of developing cancer from birth to life expectancy=100×(1-ecumulative rate100)
Trends in incidence/mortality rates were summarized as an annual percentage change (APC) by using a Joinpoint regression. APC is the average percentage change of rates and is calculated as follows [11]:
APC=Ry+1-RyRy×100=(eb1-1)×100
, where log(Ry)=b0+b1y,
log(Ry) is the natural log transformed age standardized rates.
y=year, b0=intercept, b1=slope
The survival duration for each cancer case was calculated as the interval between the date of the initial diagnosis and the date of death, date of loss to follow-up, or closing date for follow-up. The 5-year relative survival rates (RSRs) were calculated as the ratios of the observed survival of the cancer patients to the expected survival of the general population, which was derived from the standard life table provided by Statistics Korea. Trends in 5-year RSRs were evaluated as percentage differences in 5-year RSRs from 1993-1995 and 2011-2015. RSRs were calculated using the Ederer II method [14] with some minor corrections, based on an algorithm established by Paul Dickman [15].
Prevalent cases were defined as the number of cancer patients alive on January 1, 2016 among all cancer patients diagnosed between 1999 and 2015. Limited-duration prevalences were calculated using SEER*Stat software. Any p-values less than 0.05 were considered statistically significant. SEER*Stat 8.2.1 (National Cancer Institute, Bethesda, MD), Joinpoint 4.1.1 (National Cancer Institute), and SAS 9.4 (SAS Institute Inc., Cary, NC) were used in this report.

Selected Findings

1. Incidence

A total of 214,701 cases were newly diagnosed with cancer during 2015 (Table 1). Of these cases, 113,335 (52.8%) were men and 101,366 (47.2%) were women. Stomach cancer was the most commonly diagnosed cancer in 2015, followed by colorectal, thyroid, lung, and breast cancer. The overall cumulative risk of developing cancer from birth to life expectancy was 35.3%. However, the cumulative risk of developing cancer from birth to life expectancy was higher in men (37.9%) than in women (32.0%) (data not shown).
The total CR and ASR for the overall cancer incidences in 2015 were 421.4 and 258.9 per 100,000, respectively (Table 2). According to sex, the CRs for all sites combined were 445.2 in men and 397.6 in women. The ASRs were 291.7 and 241.1 in men and women, respectively. Stomach cancer (CR, 76.8) was the most common cancer in men, followed by lung (CR, 66.8), colorectal (CR, 62.5), liver (CR, 46.1), and prostate cancer (CR, 40.1). These five cancers accounted for 65.7% of the newly diagnosed cases in men during the study period. In contrast, thyroid cancer (CR, 77.1) was the most common cancer among women, followed by breast (CR, 75.1), colorectal (CR, 42.7), stomach (CR, 37.9), and lung cancer (CR, 28.4), which five cancers accounted for 65.7% of the cases in women.

2. Mortality

In 2015, the total number of deaths from cancer was 76,855, accounting for 27.9% of all deaths (Table 3). In terms of sex, 62.0% and 38.0% of cancer deaths occurred in men and women, respectively (Table 1).
The total CR and ASR for cancer deaths were 150.8 and 82.0 per 100,000, respectively, in 2015 (Table 4). The total CR and ASR for cancer deaths per 100,000 were higher among men (CR, 187.3; ASR, 119.6) than among women (CR, 114.4; ASR, 54.6).
According to cancer sites, lung cancer (CR, 49.8) was the leading cause of death in men, followed by liver (CR, 32.9), stomach (CR, 21.6), colorectal (CR, 18.5), and pancreatic cancer (CR, 11.4). The top five causes of deaths from cancer in women included lung (CR, 18.5), colorectal (CR, 14.1), stomach (CR, 11.8), liver (CR, 11.5), and pancreatic cancer (CR, 9.9).

3. Trends in cancer incidence and mortality

Fig. 1 shows the trends in cancer incidence and mortality from 1983 to 2015. The ASR for all-cancer incidence increased by 3.4% annually from 1999 to 2012, and then began to decrease from 2012 to 2015 (APC, –6.1%) (Table 5, Fig. 1). The incidence of cancers in stomach, colorectum, lung and thyroid started to decrease around 2011. Especially, the ASR for thyroid cancer has increased rapidly 22.8% from 1999 to 2011, but then decreased swiftly 13.3% annually starting in 2011. Incidence of breast cancer has increased constantly throughout the period, but the APC slowly started to decrease since 2007. Conversely, the incidence rates of cervix and liver showed a constant decrease for the whole period. The incidence of liver cancer decreased drastically starting in 2010 (Fig. 2).
The ASR for the all-cancer mortality rate has been increased until 2002 (Table 6, Fig. 1). After that year, it began to decrease (2002-2015, APC, –2.7%). Similar patterns were observed in men and women. According to cancer sites, the mortality rates for most cancers including those of the lung, liver, colorectum, gallbladder, leukemia, brain and central nervous system, cervix uteri, and thyroid started to decrease in the early 2000s. However, the mortality rates for cancers of the stomach, larynx, testis, bladder, and non-Hodgkin lymphoma decreased starting in 1999 (Fig. 3). Cancers in the pancreas, breast, and prostate showed constant increasing trends for the whole period.

4. Age-specific incidence

Leukemia was the most commonly diagnosed cancer among children aged 0-14 years (Table 7). Thyroid cancer was the most common cancer among adolescents and young adults between 15 and 34 years of age. For men, the incidence rate of cancer increased before age 70 years (Fig. 4A). Stomach cancer was the most commonly diagnosed cancer among men aged 35 to 64 years, while lung cancer was the most common among men aged ≥ 65 years. In contrast, breast cancer was most commonly diagnosed among women aged 35-64 years, while colorectal cancer was the most common among women aged ≥ 65 years. The incidence rates for thyroid and breast cancer showed an inverted U-shaped pattern when analyzed according to age (Fig. 4B).

5. Survival rates

The 5-year RSRs for all cancer combined improved remarkably in both sexes, from 41.2% in 1993-1995 to 70.7% in 2011-2015 (Table 8, Fig. 5A). After excluding thyroid cancer, the 5-year RSRs for all cancer still increased from 1993 to 2015 (Fig. 5B).
The 5-year RSR during 2011-2015 for all cancers combined was 62.8% in men and 78.4% in women, respectively. The 5-year RSR for thyroid cancer was over 100%, while the 5-year RSRs for testis, prostate, and breast cancer were over 90% in 2011-2015 for both sexes. However, the 5-year RSR for pancreatic cancer was only 10.8% in both sexes in 2011-2015.
When compared to the 5-year RSR for men in 1993-1995, prostate cancer diagnosed from 2011 to 2015 showed the most outstanding improvement, followed by stomach, leukemia, “lip, oral cavity and pharynx” and liver cancer. Among women, stomach cancer diagnosed during 2011-2015 showed the greatest improvement in 5-year RSRs compared to those between 1993 and 1995, followed by leukemia, lung, colorectal, and kidney cancer.

6. Prevalence

A total of 1,611,487 prevalent cancer cases were identified on January 1, 2016 (Table 1). Of these cases, 707,977 (43.9%) were men and 903,510 (56.1%) were women. The crude and age-standardized prevalence rates for overall cancer were 3,162.8 per 100,000 individuals and 1,956.9 per 100,000 individuals for both sexes, respectively, in 2015 (Table 9).
The five most common cancers for men were stomach (CR, 668.9), colorectal (CR, 516.8), prostate (CR, 272.8), thyroid (CR, 236.3), and liver cancer (CR, 180.2). In contrast, thyroid cancer was most common in women (CR, 1156.8), followed by breast (CR, 699.8), colorectal (CR, 349.4), stomach (CR, 340.1), and cervix uteri cancer (CR, 198.0).
Analysis of the period after cancer diagnosis revealed that thyroid (15.8%) cancer was the most prevalent cancer within 2 years after diagnosis, followed by stomach (14.3%) and colorectal cancer (13.2%) (Fig. 6). Thyroid cancer (27.4%) was most prevalent for 2-5 years, followed by stomach (14.5%) and colorectal cancer (13.6%). After 5 years, thyroid cancer (21.7%) was the most prevalent cancer, followed by stomach (17.6%) and colorectal cancer (14.0%).

Notes

Conflict of interest relevant to this article was not reported.

ACKNOWLEDGMENTS

This work was supported by a research grant from the National Cancer Center (No. 1610200), Republic of Korea. The authors are indebted to the Korea Central Cancer Registry (KCCR)-affiliated hospitals, non-KCCR-affiliated hospitals, the National Health Insurance Service and Statistics Korea for the data collection.

Notes

The Community of Population-Based Regional Cancer Registries

Chang-Hoon Kim (Busan Cancer Registry, Pusan National University Hospital), Cheol-In Yoo (Ulsan Caner Registry, Ulsan University Hospital), Jong-Hyock Park (Chungbuk Cancer Registry, Chungbuk National University Hospital), Hae-Sung Nam (Daejeon/Chungnam Cancer Registry, Chungnam National University and Hospital), Jung-Sik Huh (Jeju Cancer Registry, Jeju National University and Hospital), Jung-Ho Youm (Chonbuk Cancer Registry, Chonbuk National University Hospital), Eurah Goh (Kangwon Cancer Registry, Kangwon National University Hospital), Nam-Soo Hong (Daegu/Gyeongbuk Cancer Registry, Kyungpook National University Medical Center), Sun-Seog Kweon (Gwangju/Jeonnam Cancer Registry, Chonnam National University Hospital), Woo-Chul Kim (Incheon Cancer Registry, Inha University Hospital), Yune-Sik Kang (Gyeongnam Cancer Registry, Gyeongsang National University & Hospital)

References

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer;2013. [cited 2017 Jan 20]. Available from: http://globocan.iarc.fr.
2. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 385:117–71.
3. Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 2017; 49:292–305.
crossref
4. Jung KW, Won YJ, Oh CM, Kong HJ, Cho H, Lee DH, et al. Prediction of cancer incidence and mortality in Korea, 2015. Cancer Res Treat. 2015; 47:142–8.
crossref
5. Lee KS, Chang HS, Lee SM, Park EC. Economic burden of cancer in Korea during 2000-2010. Cancer Res Treat. 2015; 47:387–98.
crossref
6. Shin HR, Won YJ, Jung KW, Kong HJ, Yim SH, Lee JK, et al. Nationwide cancer incidence in Korea, 1999-2001: first result using the national cancer incidence database. Cancer Res Treat. 2005; 37:325–31.
crossref
7. Ajiki W, Tsukuma H, Oshima A. Index for evaluating completeness of registration in population-based cancer registries and estimation of registration rate at the Osaka Cancer Registry between 1966 and 1992 using this index. Nihon Koshu Eisei Zasshi. 1998; 45:1011–7.
8. Statistics Korea [Internet]. Daejeon: Statistics Korea;2017. [cited 2017 Jan 28]. Available from: http://kosis.kr.
9. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, et al. International classification of diseases for oncology. 3rd ed. Geneva: World Health Organization;2000.
10. World Health Organization. International statistical classification of diseases and related health problems. 10th rev. ed. Geneva: World Health Organization;1994.
11. Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER Cancer Statistics Review, 1975-2013 [Internet]. Bethesda, MD: National Cancer Institute;2016. [cited 2017 Feb 20]. Available from: http://seer.cancer.gov/csr/1975_2013/.
12. Segi M. Cancer mortality for selected sites in 24 countries (1950-1957). Sendai: Tohoku University School of Medicine;1960.
13. Day NE. Cumulative rates and cumulative risk. In : Muir C, Waterhouse J, Mack T, Powell J, Whelan S, editors. Cancer incidence in five continents, Vol. V. IARC Scientific Publications No. 88. Lyon: International Agency for Research on Cancer;1987. p. 787–9.
14. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. Bethesda, MD: National Cancer Institute;1959.
15. Paul Dickman [Internet]. Stockholm: PaulDickman.com;2016. [cited 2016 Jan 14]. Available from: http//www.pauldickman.com.

Fig. 1.
Annual age-standardized cancer incidence and death rates by sex for all sites from 1983 to 2015 in Korea. Age standardization was based on the Segi’s world standard population.
crt-2018-143f1.tif
Fig. 2.
Trends in age-standardized incidences of selected cancers by sex from 1999 to 2015 in Korea. Age standardization was based on the Segi’s world standard population. (A) Men. (B) Women.
crt-2018-143f2.tif
Fig. 3.
Annual age-standardized cancer mortalities of selected cancers by sex from 1983 to 2015 in Korea. (A) Men. (B) Women. Age-standardization was based on the Segi’s world standard population.
crt-2018-143f3.tif
Fig. 4.
Age-specific incidence rates of common cancers for 2015 in Korea. (A) Men. (B) Women.
crt-2018-143f4.tif
Fig. 5.
Trends in relative survival by year of diagnosis from 1999 to 2014. (A) All sites for both sexes. (B) All sites except thyroid cancer for both sexes.
crt-2018-143f5.tif
Fig. 6.
Prevalence of common cancer sites by time period after cancer diagnosis. Prevalent cases were defined as the number of cancer patients alive on January 1, 2016 among all cancer patients diagnosed between 1999 and 2015.
crt-2018-143f6.tif
Table 1.
Cancer incidence, deaths and prevalence by sex in Korea, 2015
Site/Type New cases
 Deaths
 Prevalent casesa)
Both sexes Men Women Both sexes Men Women Both sexes Men Women
All sites 214,701 113,335 101,366 76,855 47,678 29,177 1,611,487 707,977 903,510
Lip, oral cavity, and pharynx 3,309 2,390 919 1,170 884 286 21,827 14,656 7,171
Esophagus 2,420 2,201 219 1,531 1,401 130 9,171 8,262 909
Stomach 29,207 19,545 9,662 8,526 5,507 3,019 256,995 170,294 86,701
Colon and rectum 26,790 15,911 10,879 8,301 4,698 3,603 220,653 131,579 89,074
Liver 15,757 11,732 4,025 11,311 8,382 2,929 61,290 45,881 15,409
Gallbladderb) 6,251 3,220 3,031 4,211 2,135 2,076 19,468 9,958 9,510
Pancreas 6,342 3,359 2,983 5,439 2,908 2,531 9,517 5,031 4,486
Larynx 1,146 1,079 67 344 319 25 10,049 9,452 597
Lung 24,267 17,015 7,252 17,399 12,677 4,722 69,931 43,987 25,944
Breast 19,219 77 19,142 2,354 16 2,338 179,081 686 178,395
Cervix uteri 3,582 - 3,582 967 - 3,582 50,477 - 3,582
Corpus uteri 2,404 - 2,404 319 - 2,404 20,859 - 2,404
Ovary 2,443 - 2,443 1,055 - 2,443 18,112 - 2,443
Prostate 10,212 10,212 - 1,700 1,700 - 69,438 69,438 -
Testis 286 286 - 10 10 - 2,939 2,939 -
Kidney 4,555 3,134 1,421 952 672 280 35,333 23,862 11,471
Bladder 4,033 3,245 788 1,299 960 339 31,407 25,609 5,798
Brain and CNS 1,776 958 818 1,266 674 592 10,349 5,334 5,015
Thyroid 25,029 5,386 19,643 341 106 235 355,057 60,151 294,906
Hodgkin lymphoma 271 174 97 49 33 16 2,571 1,623 948
Non-Hodgkin lymphoma 4,396 2,519 1,877 1,771 1,026 745 27,478 15,622 11,856
Multiple myeloma 1,455 762 693 889 466 423 5,330 2,779 2,551
Leukemia 3,242 1,830 1,412 1,720 1,003 717 19,260 10,654 8,606
Other and ill defined 16,309 8,300 8,009 3,931 2,101 1,830 104,895 50,180 54,715

CNS, central nervous system.

a) Limited-duration prevalent cases on January 1, 2016. These are patients who were diagnosed between January 1, 1999 and December 31, 2015 and who were alive on January 1, 2016. Multiple primary cancer cases were counted multiple times,

b) Include the gallbladder and other/unspecified parts of the biliary tract.

Table 2.
Crude and age-standardized cancer incidence rates by sex in Korea, 2015
Site/Type Crude incidence rate per 100,000
 Age-standardized incidence rate per 100,000a)
Both sexes Men Women Both sexes Men Women
All sites 421.4 445.2 397.6 258.9 291.7 241.1
Lip, oral cavity, and pharynx 6.5 9.4 3.6 4.1 6.2 2.2
Esophagus 4.7 8.6 0.9 2.7 5.5 0.4
Stomach 57.3 76.8 37.9 33.8 49.3 20.5
Colon and rectum 52.6 62.5 42.7 30.4 40.2 22.2
Liver 30.9 46.1 15.8 18.2 29.5 8.2
Gallbladderb) 12.3 12.6 11.9 6.6 8.0 5.5
Pancreas 12.4 13.2 11.7 7.0 8.5 5.7
Larynx 2.2 4.2 0.3 1.3 2.7 0.1
Lung 47.6 66.8 28.4 26.4 42.3 14.3
Breast 37.7 0.3 75.1 24.8 0.2 49.2
Cervix uteri 7.0 - 14.1 4.6 - 9.1
Corpus uteri 4.7 - 9.4 3.1 - 6.1
Ovary 4.8 - 9.6 3.2 - 6.3
Prostate 20.0 40.1 - 11.2 25.4 -
Testis 0.6 1.1 - 0.6 1.1 -
Kidney 8.9 12.3 5.6 5.7 8.2 3.4
Bladder 7.9 12.7 3.1 4.3 8.1 1.5
Brain and CNS 3.5 3.8 3.2 2.8 3.1 2.4
Thyroid 49.1 21.2 77.1 35.2 15.1 55.6
Hodgkin lymphoma 0.5 0.7 0.4 0.5 0.6 0.4
Non-Hodgkin lymphoma 8.6 9.9 7.4 5.9 7.2 4.6
Multiple myeloma 2.9 3.0 2.7 1.6 1.9 1.4
Leukemia 6.4 7.2 5.5 5.3 6.2 4.5
Other and ill defined 32.0 32.6 31.4 19.7 22.6 17.4

CNS, central nervous system.

a) Age-adjusted using the Segi’s world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 3.
The top 10 leading causes of death in Korea, 2015
Rank Cause of death No. of deaths (%) Age-standardized death rate per 100,000a)
All causes 275,895 (100) 289.3
1 Cancer 76,855 (27.9) 82.0
2 Heart disease 28,326 (10.3) 27.9
3 Cerebrovascular disease 24,455 (8.9) 23.4
4 Pneumonia 14,718 (5.3) 13.5
5 Intentional self-harm (suicide) 13,513 (4.9) 18.3
6 Diabetes mellitus 10,558 (3.8) 10.2
7 Chronic lower respiratory diseases 7,538 (2.7) 6.8
8 Disease of liver 6,847 (2.5) 8.1
9 Transport accidents 5,539 (2.0) 7.6
10 Hypertensive diseases 5,050 (1.8) 4.6
Others 82,496 (29.9) 87.1

Source: Mortality Data, 2015, Statistics Korea [8].

a) Age-adjusted using the Segi’s world standard population.

Table 4.
Crude and age-standardized cancer mortality rates by sex in Korea, 2015
Site/Type Crude mortality rate per 100,000
 Age-standardized mortality rate per 100,000a)
Both sexes Men Women Both sexes Men Women
All sites 150.8 187.3 114.4 82.0 119.6 54.6
Lip, oral cavity, and pharynx 2.3 3.5 1.1 1.3 2.3 0.6
Esophagus 3.0 5.5 0.5 1.6 3.4 0.2
Stomach 16.7 21.6 11.8 8.9 13.8 5.4
Colon and rectum 16.3 18.5 14.1 8.5 11.8 6.1
Liver 22.2 32.9 11.5 12.6 20.9 5.4
Gallbladderb) 8.3 8.4 8.1 4.2 5.3 3.4
Pancreas 10.7 11.4 9.9 5.7 7.2 4.5
Larynx 0.7 1.3 0.1 0.4 0.8 0.0
Lung 34.1 49.8 18.5 17.9 31.2 8.2
Breast 4.6 0.1 9.2 2.8 0.0 5.5
Cervix uteri 1.9 - 3.8 1.1 - 2.0
Corpus uteri 0.6 - 1.3 0.4 - 0.7
Ovary 2.1 - 4.1 1.2 - 2.2
Prostate 3.3 6.7 - 1.6 4.3 -
Testis 0.0 0.0 - 0.0 0.0 -
Kidney 1.9 2.6 1.1 1.0 1.7 0.5
Bladder 2.5 3.8 1.3 1.2 2.4 0.5
Brain and CNS 2.5 2.6 2.3 1.7 1.9 1.5
Thyroid 0.7 0.4 0.9 0.3 0.3 0.4
Hodgkin lymphoma 0.1 0.1 0.1 0.1 0.1 0.0
Non-Hodgkin lymphoma 3.5 4.0 2.9 2.0 2.7 1.4
Multiple myeloma 1.7 1.8 1.7 1.0 1.2 0.8
Leukemia 3.4 3.9 2.8 2.2 2.8 1.7
Other and ill defined 7.7 8.3 7.2 4.3 5.5 3.5

CNS, central nervous system.

a) Age-adjusted using the world standard population,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 5.
Trends in cancer incidence rates from 1999 to 2015 in Korea
Site/Type Both sexes
 Men
 Women
1999 2015 Trend 1
 Trend 2
 1999 2015 Trend 1
 Trend 2
 1999 2015 Trend 1
 Trend 2
Year APC Year APC Year APC Year APC Year APC Year APC
All sites 210.5 258.9 1999-2012 3.4a) 2012-2015 –6.1a) 285.0 291.7 1999-2011 1.7a) 2011-2015 –3.6a) 161.1 241.1 1999-2012 5.5a) 2012-2015 –7.5a)
Lip, oral cavity, and pharynx 3.6 4.1 1999-2015 0.5a) - - 6.1 6.2 1999-2015 –0.2 - - 1.6 2.2 1999-2015 1.4a) - -
Esophagus 4.1 2.7 1999-2015 –2.3a) - - 8.8 5.5 1999-2015 –2.7a) - - 0.6 0.4 1999-2015 –1.8a) - -
Stomach 43.6 33.8 1999-2011 –0.1 2011-2015 –5.7a) 66.2 49.3 1999-2011 –0.3 2011-2015 –6.2a) 26.7 20.5 1999-2011 –0.3 2011-2015 –5.1a)
Colon and rectum 20.4 30.4 1999-2010 6.0a) 2010-2015 –4.9a) 26.2 40.2 1999-2010 6.5a) 2010-2015 –5.4a) 16.4 22.2 1999-2010 4.9a) 2010-2015 –4.3a)
Liver 27.9 18.2 1999-2010 –1.7a) 2010-2015 –4.6a) 46.8 29.5 1999-2009 –1.9a) 2009-2015 –4.2a) 12.3 8.2 1999-2010 –1.5a) 2010-2015 –5.0a)
Gallbladderb) 6.5 6.6 1999-2004 1.5 2004-2015 –0.3 8.1 8.0 1999-2015 0.0 - - 5.4 5.5 1999-2003 2.5 2003-2015 –0.6a)
Pancreas 5.6 7.0 1999-2015 1.4a) - - 7.8 8.5 1999-2015 0.7a) - - 4.0 5.7 1999-2015 2.2a) - -
Larynx 2.3 1.3 1999-2015 –3.6a) - - 4.9 2.7 1999-2015 –3.8a) - - 0.4 0.1 1999-2007 –8.9a) 2007-2015 –4.2a)
Lung 28.5 26.4 1999-2011 0.1 2011-2015 –1.8a) 51.4 42.3 1999-2005 –0.1 2005-2015 –1.6a) 12.4 14.3 1999-2012 1.9a) 2012-2015 –2.0
Breast 10.7 24.8 1999-2007 6.9a) 2007-2015 4.0a) 0.2 0.2 1999-2015 –1.1 - - 20.9 49.2 1999-2007 7.1a) 2007-2015 4.1a)
Cervix uteri 8.5 4.6 1999-2015 –3.9a) - - - - - - - - 16.3 9.1 1999-2015 –3.7a) - -
Corpus uteri 1.4 3.1 1999-2009 6.2a) 2009-2015 3.1a) - - - - - - 2.8 6.1 1999-2009 6.4a) 2009-2015 3.3a)
Ovary 2.7 3.2 1999-2015 1.6a) - - - - - - - - 5.0 6.3 1999-2015 1.8a) - -
Prostate 3.1 11.2 1999-2009 15.3a) 2009-2015 0.3 8.4 25.4 1999-2009 13.7a) 2009-2015 –0.5 - - - - - -
Testis 0.3 0.6 1999-2015 4.9a) - - 0.6 1.1 1999-2015 4.8a) - - - - - - - -
Kidney 3.0 5.7 1999-2009 6.7a) 2009-2015 1.3a) 4.5 8.2 1999-2010 6.1a) 2010-2015 0.4 1.7 3.4 1999-2009 6.6a) 2009-2015 1.1
Bladder 4.6 4.3 1999-2004 2.4a) 2004-2015 –1.5a) 9.0 8.1 1999-2005 1.5a) 2005-2015 –1.8a) 1.6 1.5 1999-2003 2.6 2003-2015 –1.7a)
Brain and CNS 2.9 2.8 1999-2008 1.3a) 2008-2015 –1.6a) 3.2 3.1 1999-2009 1.2a) 2009-2015 –2.0 2.6 2.4 1999-2007 1.5 2007-2015 –1.5a)
Thyroid 6.3 35.2 1999-2011 22.8a) 2011-2015 –13.3a) 2.1 15.1 1999-2012 22.9a) 2012-2015 –16.9a) 10.4 55.6 1999-2011 22.4a) 2011-2015 –14.4a)
Hodgkin lymphoma 0.2 0.5 1999-2015 4.1a) - - 0.4 0.6 1999-2015 3.2a) - - 0.1 0.4 1999-2015 5.3a) - -
Non-Hodgkin lymphoma 4.3 5.9 1999-2015 2.3a) - - 5.6 7.2 1999-2015 1.9a) - - 3.3 4.6 1999-2015 2.6a) - -
Multiple myeloma 1.0 1.6 1999-2015 3.3a) - - 1.2 1.9 1999-2015 3.0a) - - 0.8 1.4 1999-2015 3.5a) - -
Leukemia 4.7 5.3 1999-2015 0.9a) - - 5.5 6.2 1999-2015 1.0a) - - 3.9 4.5 1999-2015 0.7a) - -
Other and ill defined 14.4 19.7 1999-2008 3.5a) 2008-2015 1.3a) 18.1 22.6 1999-2015 1.8a) - - 11.9 17.4 1999-2011 3.8a) 2011-2015 –0.3

APC was calculated using age-standardized incidence data based on the Segi’s world standard population. APC, annual percentage change; CNS, central nervous system.

a) Significantly different from zero (p < 0.05),

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 6.
Trends in cancer mortality rates from 1999 to 2015 in Korea
Site/Type Both sexes
 Men
 Women
1999 2015 Trend 1
 Trend 2
 1999 2015 Trend 1
 Trend 2
 1999 2015 Trend 1
 Trend 2
Year APC Year APC Year APC Year APC Year APC Year APC
All sites 114.3 82.0 1999-2002 1.0 2002-2015 –2.7a) 176.6 119.6 1999-2002 1.2 2002-2015 –3.1a) 70.6 54.6 1999-2002 1.0 2002-2015 –2.2a)
Lip, oral cavity, and pharynx 1.1 1.3 1999-2015 –1.8a) - - 2.0 2.3 1999-2015 –2.1a) - - 0.4 0.6 1999-2015 –2.7a) - -
Esophagus 3.1 1.6 1999-2015 –4.4a) - - 6.8 3.4 1999-2015 –4.6a) - - 0.5 0.2 1999-2015 –5.1a) - -
Stomach 23.8 8.9 1999-2003 –3.3a) 2003-2015 –6.7a) 36.9 13.8 1999-2003 –2.6a) 2003-2015 –7.0a) 14.6 5.4 1999-2003 –4.4a) 2003-2015 –6.6a)
Colon and rectum 7.7 8.5 1999-2004 5.5a) 2004-2015 –1.3a) 10.5 11.8 1999-2004 5.9a) 2004-2015 –1.0a) 6.0 6.1 1999-2004 4.9a) 2004-2015 –1.8a)
Liver 20.4 12.6 1999-2002 0.8 2002-2015 –3.6a) 35.3 20.9 1999-2002 –0.1 2002-2015 –3.7a) 8.3 5.4 1999-2002 2.9 2002-2015 –3.7a)
Gallbladderb) 5.2 4.2 1999-2001 7.4 2001-2015 –2.7a) 6.8 5.3 1999-2001 6.2 2001-2015 –2.8a) 4.1 3.4 1999-2001 9.2 2001-2015 –2.6a)
Pancreas 5.4 5.7 1999-2015 0.3a) - - 7.6 7.2 1999-2015 –0.4a) - - 3.9 4.5 1999-2015 0.9a) - -
Larynx 1.6 0.4 1999-2015 –9.5a) - - 3.4 0.8 1999-2015 –9.1a) - - 0.4 0.0 1999-2010 –15.4a) 2010-2015 –6.2
Lung 22.4 17.9 1999-2002 1.8 2002-2015 –2.1a) 41.5 31.2 1999-2001 4.3 2001-2015 –2.5a) 9.4 8.2 1999-2002 2.3 2002-2015 –1.5a)
Breast 2.2 2.8 1999-2015 1.4a) - - 0.1 0.0 1999-2015 –4.5a) - - 4.2 5.5 1999-2015 1.7a) - -
Cervix uteri 1.4 1.1 1999-2003 8.4a) 2003-2015 –5.2a) - - - - - - 2.6 2.0 1999-2003 7.8a) 2003-2015 –4.9a)
Corpus uteri 0.1 0.4 1999-2002 51.8a) 2002-2015 3.4a) - - - - - - 0.1 0.7 1999-2002 51.6a) 2002-2015 3.8a)
Ovary 0.9 1.2 1999-2001 10.9 2001-2015 0.2 - - - - - - 1.7 2.2 1999-2001 10.2 2001-2015 0.5
Prostate 0.9 1.6 1999-2004 9.4a) 2004-2015 0.4 2.6 4.3 1999-2002 17.5a) 2002-2015 0.3 - - - - - -
Testis 0.0 0.0 1999-2015 –2.5 - - 0.1 0.0 1999-2015 2.9 - - - - - - - -
Kidney 1.1 1.0 1999-2015 –0.1 - - 1.8 1.7 1999-2015 0.0 - - 0.5 0.5 1999-2015 –0.8 - -
Bladder 1.3 1.2 1999-2015 –1.3a) - - 2.6 2.4 1999-2015 –1.6a) - - 0.5 0.5 1999-2001 10.8 2001-2015 –1.9a)
Brain and CNS 1.9 1.7 1999-2002 4.4 2002-2015 –2.0a) 2.2 1.9 1999-2015 –1.5a) - - 1.6 1.5 1999-2015 –1.4a) - -
Thyroid 0.4 0.3 1999-2003 7.0 2003-2015 –4.2a) 0.3 0.3 1999-2002 16.0 2002-2015 –4.0a) 0.5 0.4 1999-2004 4.3 2004-2015 –4.7a)
Hodgkin lymphoma 0.0 0.1 1999-2003 29.6 2003-2015 –0.2 0.0 0.1 1999-2004 19.2a) 2004-2015 –2.0 0.0 0.0 1999-2003 40.8 2003-2015 1.3
Non-Hodgkin lymphoma 2.1 2.0 1999-2015 –0.5a) - - 3.0 2.7 1999-2015 –0.8a) - - 1.4 1.4 1999-2015 –0.2 - -
Multiple myeloma 0.6 1.0 1999-2003 12.8a) 2003-2015 0.8 0.8 1.2 1999-2003 10.9a) 2003-2015 0.8 0.4 0.8 1999-2007 7.4a) 2007-2015 –1.1
Leukemia 2.9 2.2 1999-2001 1.4 2001-2015 –2.1a) 3.5 2.8 1999-2015 –1.7a) - - 2.4 1.7 1999-2015 –2.1a) - -
Other and ill defined 7.8 4.3 1999-2015 –3.1a) - - 9.0 5.5 1999-2009 –0.6 2009-2015 –6.8a) 7.0 3.5 1999-2005 –7.0a) 2005-2015 –2.2a)

APC was calculated using age-standardized incidence data based on the Segi’s world standard population. APC, annual percentage change; CNS, central nervous system.

a) Significantly different from zero (p < 0.05),

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 7.
The five common sites/types of cancer incidence by age group and sex in Korea, 2015
Rank Age (yr)
0-14 15-34 35-64 ≥ 65
Men
 1 Leukemia (4.7) Thyroid (11.9) Stomach (81.9) Lung (436.0)
 2 Non-Hodgkin lymphoma (2.7) Leukemia (3.8) Colon and rectum (62.9) Stomach (353.5)
 3 Brain and CNS (1.9) Non-Hodgkin lymphoma (2.8) Liver (56.9) Colon and rectum (300.4)
 4 Kidney (0.5) Colon and rectum (2.7) Lung (42.1) Prostate (284.2)
 5 Liver (0.4) Testis (2.3) Thyroid (33.7) Liver (178.7)
Women
 1 Leukemia (4.1) Thyroid (45.9) Breast (132.5) Colon and rectum (168.4)
 2 Brain and CNS (1.6) Breast (10.9) Thyroid (125.6) Stomach (137.0)
 3 Non-Hodgkin lymphoma (1.5) Cervix uteri (5.2) Colon and rectum (37.0) Lung (122.1)
 4 Thyroid (0.9) Ovary (3.0) Stomach (36.5) Breast (78.2)
 5 Ovary (0.6) Stomach (2.9) Lung (21.9) Live (66.3)

CNS, central nervous system.

Table 8.
Trends in the 5-year relative survival rates (%) by year of diagnosis from 1993 to 2015 in Korea
Site/Type Both sexes
 Men
 Women
1993-1995 1996-2000 2001-2005 2006-2010 2011-2015 Changea) 1993-1995 1996-2000 2001-2005 2006-2010 2011-2015 Changea) 1993-1995 1996-2000 2001-2005 2006-2010 2011-2015 Changea)
All sites 41.2 44.0 54.0 65.2 70.7 29.5 31.7 35.3 45.4 56.5 62.8 31.1 53.4 55.3 64.2 74.2 78.4 25.0
Lip, oral cavity, and pharynx 41.1 46.7 54.3 60.6 64.5 23.4 35.8 41.1 49.4 56.4 60.7 24.9 58.1 63.8 67.8 71.7 74.1 16.0
Esophagus 12.7 15.2 21.4 29.6 36.0 23.3 11.8 14.3 20.6 29.0 35.7 23.9 23.7 24.2 29.7 36.5 39.3 15.6
Stomach 42.8 46.6 57.8 68.1 75.4 32.6 43.0 46.9 58.4 68.7 76.3 33.3 42.6 46.0 56.5 66.7 73.7 31.1
Colon and rectum 54.8 58.0 66.7 73.5 76.3 21.5 55.3 59.0 68.5 75.4 78.0 22.7 54.2 56.8 64.3 70.8 73.6 19.4
Liver 10.7 13.2 20.4 28.1 33.6 22.9 9.9 12.9 20.3 28.1 34.1 24.2 13.6 14.2 20.9 28.1 32.2 18.6
Gallbladderb) 17.3 19.7 23.1 26.8 29.1 11.8 16.6 20.3 23.5 27.7 30.2 13.6 18.0 19.1 22.7 25.9 28.0 10.0
Pancreas 9.4 7.6 8.4 8.4 10.8 1.4 8.8 7.3 8.4 8.1 10.3 1.5 10.1 8.1 8.5 8.7 11.5 1.4
Larynx 59.7 62.3 66.3 72.9 75.5 15.8 60.2 62.8 66.9 73.2 75.9 15.7 55.4 57.8 58.9 67.6 69.9 14.5
Lung 11.3 12.7 16.5 20.1 26.7 15.4 10.4 11.6 15.2 17.9 22.7 12.3 14.2 16.2 20.1 25.8 35.8 21.6
Breast 77.9 83.2 88.6 91.1 92.3 14.4 75.1 85.6 87.2 89.9 87.1 12.0 78.0 83.2 88.6 91.1 92.3 14.3
Cervix uteri 77.5 80.0 81.4 80.5 79.9 2.4 - - - - - - 77.5 80.0 81.4 80.5 79.9 2.4
Corpus uteri 81.5 81.8 84.5 86.4 87.8 6.3 - - - - - - 81.5 81.8 84.5 86.4 87.8 6.3
Ovary 58.7 58.9 61.8 61.1 64.1 5.4 - - - - - - 58.7 58.9 61.8 61.1 64.1 5.4
Prostate 55.9 67.2 80.4 91.1 94.1 38.2 55.9 67.2 80.4 91.1 94.1 38.2 - - - - - -
Testis 85.4 90.4 90.7 93.1 95.6 10.2 85.4 90.4 90.7 93.1 95.6 10.2 - - - - - -
Kidney 62.0 66.1 73.6 78.4 82.2 20.2 60.8 64.4 73.0 78.2 81.6 20.8 64.5 69.7 74.7 78.8 83.6 19.1
Bladder 69.1 73.1 75.7 76.7 75.8 6.7 70.0 74.8 77.5 78.8 77.8 7.8 65.5 66.3 68.8 68.6 67.7 2.2
Brain and CNS 38.5 39.0 40.9 42.8 40.7 2.2 37.2 37.5 40.2 41.4 39.1 1.9 40.2 40.7 41.7 44.4 42.6 2.4
Thyroid 94.2 94.9 98.4 99.9 100.3 6.1 87.2 89.5 96.0 100.1 100.6 13.4 95.4 95.9 98.7 99.9 100.2 4.8
Hodgkin lymphoma 68.0 71.2 76.7 81.0 82.2 14.2 67.6 68.1 74.7 80.7 82.8 15.2 68.6 77.4 80.7 81.6 81.2 12.6
Non-Hodgkin lymphoma 46.6 50.8 55.9 59.3 62.9 16.3 45.3 48.9 54.9 59.1 62.4 17.1 48.7 53.5 57.4 59.6 63.6 14.9
Multiple myeloma 22.1 19.8 29.6 34.9 40.9 18.8 21.1 17.8 29.8 35.0 40.6 19.5 23.3 22.1 29.4 34.8 41.3 18.0
Leukemia 26.5 33.3 42.0 47.6 51.0 24.5 26.2 32.3 41.8 46.8 51.1 24.9 26.8 34.6 42.2 48.6 50.8 24.0
Other and ill defined 42.1 45.9 57.6 67.2 72.2 30.1 37.4 42.4 53.8 63.4 68.9 31.5 47.4 50.0 61.8 71.0 75.5 28.1

CNS, central nervous system.

a) Percentage change in 5-year relative survival from 1993 to 1995 and 2011 to 2015,

b) Includes the gallbladder and other/unspecified parts of the biliary tract.

Table 9.
Crude and age-standardized rates of cancer prevalence by sex on January 1, 2016 in Korea
Site/Type Crude prevalence rate per 100,000a)
 Age-standardized prevalence rate per 100,000b)
Both sexes Men Women Both sexes Men Women
All sites 3,162.8 2,781.0 3,544.1 1,956.9 1,826.6 2,171.5
Lip, oral cavity, and pharynx 42.8 57.6 28.1 26.8 37.9 17.2
Esophagus 18.0 32.5 3.6 10.3 20.6 1.8
Stomach 504.4 668.9 340.1 291.5 425.6 180.9
Colon and rectum 433.1 516.8 349.4 248.2 330.6 181.7
Liver 120.3 180.2 60.4 73.5 116.8 34.2
Gallbladderc) 38.2 39.1 37.3 21.1 24.7 18.4
Pancreas 18.7 19.8 17.6 11.1 12.9 9.7
Larynx 19.7 37.1 2.3 11.2 23.6 1.2
Lung 137.2 172.8 101.8 78.7 110.2 54.5
Breast 351.5 2.7 699.8 221.7 1.7 435.9
Cervix uteri 99.1 - 198.0 61.5 - 120.0
Corpus uteri 40.9 - 81.8 26.1 - 51.2
Ovary 35.5 - 71.0 24.2 - 48.1
Prostate 136.3 272.8 - 71.3 170.0 -
Testis 5.8 11.5 - 5.2 10.3 -
Kidney 69.3 93.7 45.0 43.5 62.0 27.1
Bladder 61.6 100.6 22.7 33.7 64.1 10.6
Brain and CNS 20.3 21.0 19.7 17.2 18.3 16.1
Thyroid 696.8 236.3 1,156.8 464.9 160.2 767.5
Hodgkin lymphoma 5.0 6.4 3.7 4.2 5.1 3.2
Non-Hodgkin lymphoma 53.9 61.4 46.5 38.2 45.9 31.1
Multiple myeloma 10.5 10.9 10.0 6.1 7.0 5.4
Leukemia 37.8 41.8 33.8 35.2 39.2 31.1
Other and ill defined 205.9 197.1 214.6 131.4 139.9 124.4

CNS, central nervous system.

a) Crude prevalence rate: number of prevalent cases divided by the corresponding person-years of observation. Prevalent cases were defined as patients who were diagnosed between January 1, 1999 and December 31, 2015 and who were alive on January 1, 2016. Multiple primary cancer cases were counted multiple times,

b) Age-adjusted using the Segi’s world standard population,

c) Includes the gallbladder and other/unspecified parts of the biliary tract.

TOOLS
Similar articles